KRX/207940 (KRX/207940)

Korea Stock Exchange: KRX/207940 · KRW

₩1,372,000

-2061.09 (-0.1%)· Recorded snapshot

Market cap	63.4T
Revenue (ttm)	5.1T
Net income (ttm)	2T
EPS (ttm)	₩45,556
Shares out	46.2M
P/E (trailing)	30.1x
P/E (forward)	30.6x
Volume	51,996
Beta	0.19

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5.1T
Net income (ttm): 2T
EPS (ttm): ₩45,556
P/E (trailing): 30.1x
P/E (forward): 30.6x
Market cap: 63.4T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E30.6

P25 n/aP50 n/aP75 n/a

Trailing P/E30.1

P25 n/aP50 n/aP75 n/a

ROE18.5

P25 n/aP50 n/aP75 n/a

ROIC23.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All KRX/207940 indicators

Market & fundamental data

Available fields

238

Groups with data

Currency

KRW

Showing 238 of 238 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	KRW
Country	South Korea
Country code	KR
Earnings date	2026-10-21
Employees	5,326
Employees change	279
Employees growth	5.53%
Enterprise value	KRW 62.5T
Exchange	Korea Stock Exchange
Financial currency	KRW
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2011
Industry	Biotechnology
Is primary listing	Yes
ISIN number	KR7207940008
Last earnings date	2026-10-21
Last refreshed	2026-10-28
Last stock split date	2025-10-30
Last stock split type	Reverse
Market cap	KRW 63.4T
Next earnings date	2027-01-20
Price	KRW 1,372,000.00
Price currency	KRW
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	krx/207940
Website	https://samsungbiologics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	37.84x
Average P/E ratio (10Y)	94.84x
Average P/E ratio (3Y)	52.4x
Average P/E ratio (5Y)	73.35x
Earnings yield	3.32%
EV/Earnings	31.48x
EV/EBIT	26.81x
EV/EBITDA	22.08x
EV/FCF	38.36x
EV/Sales	12.2x
FCF / EV yield	2.61%
FCF yield	2.57%
Forward P/E	30.58x
Graham number	430538.90514
Graham upside	-68.62%
Industry forward P/E	31.23x
Industry P/E	53.25x
Lynch fair value	KRW 1,138,910.03
Lynch upside	-16.99%
P/B ratio	7.59x
P/E ratio	30.12x
P/FCF ratio	38.96x
P/OCF ratio	26.07x
P/S ratio	12.39x
PEG ratio	1.54x
Price / tangible book value	7.66x
Price/EBITDA ratio	22.44x
Sector forward P/E	24.95x
Sector P/E	49.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	45.48%
EBITDA margin	55.21%
Effective tax rate	24.9%
FCF margin	31.8%
Gross margin	54.21%
Operating margin	45.48%
Pretax margin	48.08%
Profit margin	38.75%
Profit per employee	KRW 372.6M
Profitable quarters	29
Profitable years	8
Revenue per employee	KRW 961.6M
ROA	9.57%
ROA (5Y)	5.6%
ROCE	24.04%
ROE	18.53%
ROE (5Y)	11.27%
ROIC	23.55%
ROIC (5Y)	11.27%
Tax / revenue	11.97%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	64%
EPS growth (Q)	32.91%
EPS growth (QoQ)	-8.22%
EPS growth 10Y	-1.79%
EPS growth 3Y	36.69%
EPS growth 5Y	42.4%
EPS growth years	6
FCF growth	256.7%
FCF growth (Q)	38.23%
FCF growth (QoQ)	-21.26%
FCF growth 3Y	93.85%
Gross profit growth	60.71%
Gross profit growth (Q)	23.94%
Gross profit growth 3Y	17.51%
Gross profit growth 5Y	38.84%
Net income growth	54.31%
Net income growth (Q)	32.76%
Net income growth (QoQ)	-8.22%
Net income growth 3Y	33.95%
Net income growth 5Y	42.75%
Net income growth years	6
OCF growth	4.18%
OCF growth (Q)	19.38%
OCF growth (QoQ)	-18.61%
OCF growth 3Y	23.32%
OCF growth 5Y	103.96%
Operating income growth	48.06%
Operating income growth (Q)	22.89%
Operating income growth 3Y	29.09%
Operating income growth 5Y	42.95%
Revenue growth	50.31%
Revenue growth (Q)	30.24%
Revenue growth (QoQ)	5.07%
Revenue growth 10Y	38.7%
Revenue growth 3Y	14.34%
Revenue growth 5Y	31.09%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	KRW -805.6B
Depreciation and amortization	KRW 498.7B
EBIT	KRW 2.3T
EBITDA	KRW 2.8T
EPS	KRW 45,556.40
FCF per share	KRW 35,215.66
Financing cash flow	KRW -510.6B
Free cash flow	KRW 1.6T
Gross profit	KRW 2.8T
Income taxes	KRW 613.1B
Investing cash flow	KRW -2.4T
Net borrowing	KRW -202.2B
Net cash flow	KRW -420.9B
Net income	KRW 2T
Operating income	KRW 2.3T
Revenue	KRW 5.1T

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	12.47
Book value per share	KRW 180,839.32
Debt / EBITDA	0.44
Debt / equity	0.15
Debt / FCF	0.76
Interest coverage	71.57
Long-term assets	KRW 7.3T
Long-term liabilities	KRW 1.3T
Net cash (debt)	KRW 971.7B
Net cash / market cap	1.53%
Net cash growth	328.4%
Net debt / EBITDA	-0.34
Net debt / equity	-0.12
Net debt / FCF	-0.6
Piotroski F-Score	8
Property, plant and equipment	KRW 6.7T
Shareholders' equity	KRW 8.4T
Tangible book value	KRW 8.3T
Tangible book value per share	KRW 179,178.53
Total assets	KRW 12.7T
Total cash	KRW 2.2T
Total debt	KRW 1.2T
Total liabilities	KRW 4.3T
WACC	5.23%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.34
Current assets	KRW 5.3T
Current liabilities	KRW 3T
Current ratio	1.8
Inventory turnover	0.87
Net working capital	KRW 558.6B
Quick ratio	0.95
Working capital	KRW 2.4T
Working capital turnover	2.31

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	5.91%
Shareholder yield	5.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	KRW 1,444,440.00
1D price change	-0.15%
1M price change	0.44%
1M total return	1.12%
1W price change	-3.18%
1W total return	-3.18%
1Y price change	-26.13%
1Y return CAGR	-9.87%
1Y total return	-9.86%
20-day SMA	KRW 1,337,950.00
200-day SMA	KRW 1,518,680.00
3M price change	-11.2%
3M total return	-10.59%
3Y price change	23.42%
3Y return CAGR	14.62%
3Y total return	50.61%
50-day SMA	KRW 1,423,220.00
50-day SMA vs 200-day SMA	50under200
52-week high	KRW 1,987,000.00
52-week high date	2026-01-15
52-week low	KRW 1,150,000.00
52-week low date	2026-10-15
5Y price change	-0.63%
5Y return CAGR	4.15%
5Y total return	22.55%
6M price change	-9.08%
6M total return	-8.46%
All-time high	KRW 1,987,000.00
All-time high date	2026-01-15
All-time low	KRW 192,960.76
All-time low date	2016-11-10
Average true range (ATR)	KRW 65,050.87
Average volume	81.3K
Beta (1Y)	0.11
Beta (2Y)	0.24
Beta (5Y)	0.19
Change from 52-week high	-30.95%
Change from 52-week low	19.3%
Change from all-time high	-30.95%
Change from all-time low	611.03%
Change from open	0.15%
Day's gap	-0.29%
Dollar volume	KRW 71.3B
High price	KRW 1,399,000.00
Low price	KRW 1,360,000.00
Monthly RSI	45.08
Open price	KRW 1,370,000.00
Position in 52-week range	30.77%
Previous close	KRW 1,374,000.00
Price vs 150-day SMA	-5.02%
Price vs 20-day SMA	2.54%
Price vs 200-day SMA	-9.66%
Price vs 50-day SMA	-3.6%
Relative volume	0.66
RSI	49.93
Sharpe ratio	0.25
Sharpe ratio (3Y)	0.38
Sharpe ratio (5Y)	0.16
Sortino ratio	0.53
Sortino ratio (3Y)	0.78
Sortino ratio (5Y)	0.44
Volume	52K
Weekly RSI	43.84
YTD price change	-19.06%
YTD total return	-18.51%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.8M
Shares change (QoQ)	0%
Shares change (YoY)	-5.91%
Shares held by insiders	0%
Shares held by institutions	14.04%
Shares outstanding	46.2M

Deeper analysis on KRX/207940

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KRX/207940 report

Is a complete KRX/207940 research report available?

No complete published report is available for krx/207940 (KRX/207940) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

KRX/207940 (KRX/207940)

Price

Financial snapshot

Fair-value bridge

Latest news · KRX/207940

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KRX/207940 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KRX/207940

Frequently asked questions